Fred Mermelstein Ph.D.
Fred Mermelstein Ph.D. currently serves as President and CEO of Dynamic Cell Therapies since its founding in 2020 and Chairman of the board of Courage Therapeutics since its founding in 2019. Between 2003-2010, Dr. Mermelstein founded Javelin Pharmaceuticals, Inc. (JAV), until its sale to Hospira, Inc., now Pfizer. He served as CEO and President of Javelin, which developed Dyloject®, an injectable anti-inflammatory for the treatment of post-operative pain. He founded PolaRx Biopharmaceuticals, Inc., in 1997, where he also served as Chief Scientific Officer until 1999, and on the team responsible for bringing Trisenox® (Arsenic Trioxide for the treatment of Acute Promyelocytic Leukemia) to NDA completion, now marketed and sold worldwide by Teva. He also served on the board of NX Development Corp., between 2011-2018 which brought Gliolan® to the market in the United States prior to its acquisition by SBI Pharma, Inc. Between 2008 and 2018, Dr. Mermelstein was a co-founder and served as Chairman of the Board of Pear Tree Pharmaceuticals, until its sale to Daré Bioscience, Inc. Dr. Mermelstein currently serves on several boards, including the Harvard Institute of RNA Medicine, Rogosin Institute and Cornell-Weill Medical Center. He has served as a mentor to the Harvard Medical School Biotech Incubator and Lecturer, Department of Neurobiology, Harvard Medical School since 2013. Dr. Mermelstein has held several senior executive positions in start-up and emerging biotechnology companies. Dr. Mermelstein holds a dual Ph.D. in Pharmacology and Toxicology from Rutgers University and UMDNJ. He completed his post-doctoral training at UMDNJ supported by two grant awards, a National Institutes of Health fellowship and a Howard Hughes Medical Institute fellowship in the Department of Biochemistry.